Navigation Links
Mast Therapeutics Prices Public Offering Of Units
Date:6/14/2013

t Therapeutics cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that are based on the Company's current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements regarding the timing and closing of the offering, the net proceeds from the offering and their intended use and the Company's development plans for MST-188 in complications of peripheral arterial disease, including the timing of the initiation of the planned phase 2 study in acute limb ischemia.  Among the factors that could cause or contribute to material differences between the Company's actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: whether or when the offering will be completed; a shift in the allocation of the Company's resources from sickle cell disease to other indications, including acute limb ischemia, acute decompensated heart failure, blood transfusion and/or resuscitation of shock following major trauma; delays in the commencement of clinical studies, including as a result of difficulties in obtaining regulatory agency agreement on clinical development plans or clinical study design, opening trial sites, enrolling study subjects and manufacturing sufficient quantities of clinical trial material; the potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of the planned phase 2 clinical study of MST-188 in acute limb ischemia; and other risks and uncertainties more fully described in the Company's press releases and periodic filings with the Securities and Exchange Commission, including the Form S-1/A registration statement filed on June 14, 2013. The Company's public filings with the Securities and Exchange Commission are available at
SOURCE Mast Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... This news release is available in German . ... photonic crystal around several quantum dots in a semiconductor layer. ... a consequence of atomic processes. If a short laser pulse ... modified and the quantum dot experiences a change in the ... slow down the emission of light by the dot. As ...
(Date:9/30/2014)... , Sept. 30, 2014 Pacific Northwest ... Summary Global Markets Direct,s, ,Pacific Northwest ... provides an overview of the Pacific Northwest Biotechnology, ... report provides comprehensive information on the current therapeutic ... with comparative analysis at various stages, therapeutics assessment ...
(Date:9/30/2014)... Over the last decade, the laboratory filtration market ... and increased acceptance of new filtration technologies in end ... are also catalyzing the growth of laboratory filtration market. ... grow at a strong CAGR during the forecast period ... million by 2019. The market is mainly driven by ...
(Date:9/30/2014)... 30, 2014 CORD:USE Cord Blood Bank – ... it has entered into an Equity and Exclusive Services ... licensed a series of patented technologies for the isolation of ... applications.  Tianhe is performing Phase I/II clinical trials in ... using Tianhe,s Stem Cell Educator Therapy showing ...
Breaking Biology Technology:Ultrafast remote switching of light emission 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 2Pacific Northwest Biotechnology, LLC - Product Pipeline Review - 2014 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 2CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 3CORD:USE is Pleased to Announce it has Partnered with Tianhe Stem Cell Biotechnologies, Developer of Cord Blood Stem Cell Therapy Showing Promising Results in Clinical Trials for the Treatment of Diabetes and Autoimmune Diseases 4
... , , WASHINGTON , Jan. 27 ... which are increasingly used for research and therapeutic interventions, but extracting ... have found evidence that fat tissue, known as adipose tissue, may ... called hematopoietic stem and progenitor cells (HSPCs), according to a ...
... , , , , , , ... Biologic,Products, Inc. (Nasdaq: CBPO ) ("China Biologic," or the "Company"), ... responded to,allegations regarding the Company, certain members of its Board of ... online,financial websites. , The article, which was ...
... Obtain Stem Cells From Embryos , WHITE PLAINS, N.Y. ... reprogrammed adult cells into embryonic-like stem cells has been chosen to receive ... Shinya Yamanaka , MD, PhD, of the Gladstone Institute of Cardiovascular Disease, ... will be honored with the 2010 March of Dimes Prize for his ...
Cached Biology Technology:Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 2Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 3Fat Tissue May Be a Source of Valuable Blood Stem Cells, Study Says 4China Biologic Products Responds to Allegations on Financial Websites 2China Biologic Products Responds to Allegations on Financial Websites 3China Biologic Products Responds to Allegations on Financial Websites 4China Biologic Products Responds to Allegations on Financial Websites 5March of Dimes Awards $250,000 Prize to Scientist Who Discovered How to Reprogram Human Cells 2
(Date:9/30/2014)... research, involving mice and published in the October 2014 ... , suggests that just because you can do ... team of Italian scientists have found that using marijuana ... immune system. This damage may result in autoimmune diseases ... bowel disease and rheumatoid arthritis in adulthood. , "I ...
(Date:9/30/2014)... MILFORD, Mass. , Sept. 30, 2014 ... process control solutions for the biotech and ... of its new RECONN Bioprocess Manager, an ... reporting solution geared towards bioprocess development laboratories. ... facilities have disparate bioreactor and analyzer systems. ...
(Date:9/29/2014)... A new study confirms that the exposure to tar ... than of regular cigarettes. Similarly, exposure to nicotine ... increasingly popular type of cigarette in several countries around ... of certain toxic chemicals in the smoke of these ... because lower levels of chemicals in the smoke are ...
Breaking Biology News(10 mins):Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2Slim cigarette smokers not exposed to more harmful chemicals 2
... Hall of Fame quarterback Dan Marino and VitaCore Health ... specific nutritional supplements based on authentic sciences. Marino joined ... develop health products that will strongly impact how consumers ... specifically in terms of their joints, heart, wellbeing, endurance, ...
... The stories they could tell, these fishes that once swam ... In the 1960s and ,70s, Richard Rosenblatt, a marine ... on field expeditions to remote places to study the fishes ... waters, Rosenblatt and other scientists retrieved hundreds of specimens of ...
... (BRONX, NY) Scientists at Albert Einstein ... a desktop genome analyzer and browser that allows biologists ... data. The open-source software, called GenPlay, is described in ... genomic data is analyzed mainly by information specialists rather ...
Cached Biology News:Dan Marino Teams up with VitaCore Health Products 2Dan Marino Teams up with VitaCore Health Products 3'Library of Fishes' to feature thousands of specimens from remote locations 2'Library of Fishes' to feature thousands of specimens from remote locations 3Einstein offers easy-to-use genome analyzer to scientific community 2